Cargando…

APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates

We examined the impact of APOE genotype on plasma lipids and glucose in a secondary analysis of data from a five-arm, randomised controlled, parallel dietary intervention trial (‘RISCK’ study), to investigate the impact of replacing saturated fatty acids (SFA) with either monounsaturated fat (MUFA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, Bruce A., Walker, Celia G., Jebb, Susan A., Moore, Carmel, Frost, Gary S., Goff, Louise, Sanders, Tom A. B., Lewis, Fiona, Griffin, Margaret, Gitau, Rachel, Lovegrove, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213759/
https://www.ncbi.nlm.nih.gov/pubmed/30336580
http://dx.doi.org/10.3390/nu10101524
_version_ 1783367847429275648
author Griffin, Bruce A.
Walker, Celia G.
Jebb, Susan A.
Moore, Carmel
Frost, Gary S.
Goff, Louise
Sanders, Tom A. B.
Lewis, Fiona
Griffin, Margaret
Gitau, Rachel
Lovegrove, Julie A.
author_facet Griffin, Bruce A.
Walker, Celia G.
Jebb, Susan A.
Moore, Carmel
Frost, Gary S.
Goff, Louise
Sanders, Tom A. B.
Lewis, Fiona
Griffin, Margaret
Gitau, Rachel
Lovegrove, Julie A.
author_sort Griffin, Bruce A.
collection PubMed
description We examined the impact of APOE genotype on plasma lipids and glucose in a secondary analysis of data from a five-arm, randomised controlled, parallel dietary intervention trial (‘RISCK’ study), to investigate the impact of replacing saturated fatty acids (SFA) with either monounsaturated fat (MUFA) or carbohydrate of high or low glycaemic index (GI) on CVD risk factors and insulin sensitivity. We tested the impact of APOE genotype (carriage of E2 and E4 alleles versus E3/E3), determined retrospectively, on plasma lipids, lipoproteins and glucose homeostasis at baseline (n = 469), and on the change in these variables after 24 weeks of dietary intervention (n = 389). At baseline, carriers of E2 (n = 70), E4 (n = 125) and E3/E3 (n = 274) expressed marked differences in total plasma cholesterol (TC, p = 0.001), low density lipoprotein cholesterol (LDL-C, p < 0.0001), apolipoprotein B (apo B, p < 0.0001) and total to high density lipoprotein cholesterol ratio (TC:HDL-C, p = 0.002), with plasma concentrations decreasing in the order E4 > E3/E3 > E2. Following intervention, there was evidence of a significant diet x genotype interaction with significantly greater decreases in TC (p = 0.02) and apo B (p = 0.006) among carriers of E4 when SFA was replaced with low GI carbohydrate on a lower fat diet (TC −0.28 mmol/L p = 0.03; apo B −0.1 g/L p = 0.02), and a relative increase in TC (in comparison to E3/E3) when SFA was replaced with MUFA and high GI carbohydrates (TC 0.3 mmol/L, p = 0.03). Among carriers of E2 (compared with E3/E3) there was an increase in triacylglycerol (TAG) when SFA was replaced with MUFA and low GI carbohydrates 0.46 mmol/L p = 0.001). There were no significant interactions between APOE genotype and diet for changes in indices of glucose homeostasis. In conclusion, variations in APOE genotype led to differential effects on the lipid response to the replacement of SFA with MUFA and low GI carbohydrates.
format Online
Article
Text
id pubmed-6213759
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62137592018-11-06 APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates Griffin, Bruce A. Walker, Celia G. Jebb, Susan A. Moore, Carmel Frost, Gary S. Goff, Louise Sanders, Tom A. B. Lewis, Fiona Griffin, Margaret Gitau, Rachel Lovegrove, Julie A. Nutrients Article We examined the impact of APOE genotype on plasma lipids and glucose in a secondary analysis of data from a five-arm, randomised controlled, parallel dietary intervention trial (‘RISCK’ study), to investigate the impact of replacing saturated fatty acids (SFA) with either monounsaturated fat (MUFA) or carbohydrate of high or low glycaemic index (GI) on CVD risk factors and insulin sensitivity. We tested the impact of APOE genotype (carriage of E2 and E4 alleles versus E3/E3), determined retrospectively, on plasma lipids, lipoproteins and glucose homeostasis at baseline (n = 469), and on the change in these variables after 24 weeks of dietary intervention (n = 389). At baseline, carriers of E2 (n = 70), E4 (n = 125) and E3/E3 (n = 274) expressed marked differences in total plasma cholesterol (TC, p = 0.001), low density lipoprotein cholesterol (LDL-C, p < 0.0001), apolipoprotein B (apo B, p < 0.0001) and total to high density lipoprotein cholesterol ratio (TC:HDL-C, p = 0.002), with plasma concentrations decreasing in the order E4 > E3/E3 > E2. Following intervention, there was evidence of a significant diet x genotype interaction with significantly greater decreases in TC (p = 0.02) and apo B (p = 0.006) among carriers of E4 when SFA was replaced with low GI carbohydrate on a lower fat diet (TC −0.28 mmol/L p = 0.03; apo B −0.1 g/L p = 0.02), and a relative increase in TC (in comparison to E3/E3) when SFA was replaced with MUFA and high GI carbohydrates (TC 0.3 mmol/L, p = 0.03). Among carriers of E2 (compared with E3/E3) there was an increase in triacylglycerol (TAG) when SFA was replaced with MUFA and low GI carbohydrates 0.46 mmol/L p = 0.001). There were no significant interactions between APOE genotype and diet for changes in indices of glucose homeostasis. In conclusion, variations in APOE genotype led to differential effects on the lipid response to the replacement of SFA with MUFA and low GI carbohydrates. MDPI 2018-10-17 /pmc/articles/PMC6213759/ /pubmed/30336580 http://dx.doi.org/10.3390/nu10101524 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Griffin, Bruce A.
Walker, Celia G.
Jebb, Susan A.
Moore, Carmel
Frost, Gary S.
Goff, Louise
Sanders, Tom A. B.
Lewis, Fiona
Griffin, Margaret
Gitau, Rachel
Lovegrove, Julie A.
APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title_full APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title_fullStr APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title_full_unstemmed APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title_short APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates
title_sort apoe4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein b than wild type (e3/e3), after replacement of dietary saturated fats with low glycaemic index carbohydrates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213759/
https://www.ncbi.nlm.nih.gov/pubmed/30336580
http://dx.doi.org/10.3390/nu10101524
work_keys_str_mv AT griffinbrucea apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT walkerceliag apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT jebbsusana apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT moorecarmel apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT frostgarys apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT gofflouise apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT sanderstomab apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT lewisfiona apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT griffinmargaret apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT gitaurachel apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates
AT lovegrovejuliea apoe4genotypeexertsgreaterbenefitinloweringplasmacholesterolandapolipoproteinbthanwildtypee3e3afterreplacementofdietarysaturatedfatswithlowglycaemicindexcarbohydrates